Evidence map›Paper›PMID 39403791›Full record

ArticleAdvanced healthcare materials2025

Electrode Droplet Microarray (eDMA): An Impedance Platform for Label-Free Parallel Monitoring of Cellular Drug Response in Nanoliter Droplets.

Meijun Zhou, Joaquin E Urrutia Gomez, Nikolaj K Mandsberg, Sida Liu, Sabine Schmidt, Matthias Meier, Pavel A Levkin, Heinz-Georg Jahnke, Anna Popova

Abstract read
In one paragraph

Article in Advanced healthcare materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Meijun ZhouInstitute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Karlsruhe Institute of Technology, Kaiserstrasse 12, 76131, Karlsruhe, Germany.
Joaquin E Urrutia GomezInstitute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Karlsruhe Institute of Technology, Kaiserstrasse 12, 76131, Karlsruhe, Germany.ORCID 0000-0001-5411-9689
Nikolaj K MandsbergInstitute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Karlsruhe Institute of Technology, Kaiserstrasse 12, 76131, Karlsruhe, Germany.ORCID 0000-0003-3285-3887
Sida LiuInstitute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Karlsruhe Institute of Technology, Kaiserstrasse 12, 76131, Karlsruhe, Germany.
Sabine SchmidtCentre for Biotechnology and Biomedicine, Biochemical Cell Technology, Leipzig University, Deutscher Platz 5, D-04103, Leipzig, Germany.
Matthias MeierCentre for Biotechnology and Biomedicine, Biochemical Cell Technology, Leipzig University, Deutscher Platz 5, D-04103, Leipzig, Germany.
Pavel A LevkinInstitute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Karlsruhe Institute of Technology, Kaiserstrasse 12, 76131, Karlsruhe, Germany.
Heinz-Georg JahnkeCentre for Biotechnology and Biomedicine, Biochemical Cell Technology, Leipzig University, Deutscher Platz 5, D-04103, Leipzig, Germany.
Anna PopovaInstitute of Biological and Chemical Systems - Functional Molecular Systems (IBCS-FMS), Karlsruhe Institute of Technology, Kaiserstrasse 12, 76131, Karlsruhe, Germany.ORCID 0000-0001-7054-0609

Funding

Carlsberg Foundation CF21-0614Deutsche Forschungsgemeinschaft 406232485Deutsche Forschungsgemeinschaft LE 2936/9-1Federal Ministry for Economics Affairs and Climate Action of Germany (BMWK) 46SKD023X
6 · The paper itself

Abstract

Label-free real-time monitoring of cellular behavior using impedance spectroscopy is important for drug development and toxicological assessments. Parallelization and miniaturization of such experiments are essential for increasing throughput and enabling experiments with low abundant stem or primary cells. Traditional methods are not miniaturized and require large volumes of reagents and number of cells, limiting their suitability for cost effective high-throughput screening of cells of limited availability. Here, the fabrication, optimization, and application of a bioelectrical signaling monitoring system - electrode droplet microarray (eDMA) are demonstrated. The eDMA platform is based on preparation of a hydrophilic-superhydrophobic patterns covering an array of individually addressable microelectrodes, which confines cells to individual microelectrodes, allowing for parallel, real-time, and label-free detection of cellular responses to drug treatments in nanoliter droplets. The real-time monitoring of cytotoxic effect of an anticancer drug is demonstrated over 48 h with real-time calculation of the half-inhibitory concentration (IC50) values through impedance spectroscopy. This demonstrates eDMA's ability to dynamically assess responses to various drugs in parallel at any given time point, which is crucial for functional personalized oncology. Specifically, the platform can be employed for monitoring anticancer drug toxicity using limited patient samples, where the miniaturization provided by eDMA is essential.

Indexed as

Antineoplastic AgentsDielectric SpectroscopyMicroarray AnalysisToxicity TestsCell Line, TumorDrug Evaluation, PreclinicalDrug Screening Assays, AntitumorElectric ImpedanceHumansHydrophobic and Hydrophilic InteractionsMicroelectrodesAntineoplastic Agentsdrug screeningelectrode droplet microarrayimpedancelabel‐free

Identifiers

PMID39403791
PMCPMC11773094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.